CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Apr 1, 2013 → Aug 1, 2014
NCT ID
NCT01838850About CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placebo
CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placebo is a phase 3 stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01838850. Target conditions include Essential Hypertension.
What happened to similar drugs?
15 of 20 similar drugs in Essential Hypertension were approved
Approved (15) Terminated (2) Active (5)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01838850 | Phase 3 | Completed |
Competing Products
20 competing products in Essential Hypertension